Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

NCT03053167 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

ColoRectal Cancer

Interventions

DRUG: Irinotecan
DRUG: Raltitrexed

Sponsor

China Medical University, China

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]